MenQuadfi®, Meningococcal (Groups A, C, Y, W) conjugate vaccine – Expanded indication
May 23, 2025 - The FDA approved Sanofi’s MenQuadfi, Meningococcal (Groups A, C, Y, W) conjugate vaccine, for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals 6 weeks of age and older.
Top